The rights issue as such is no surprise since the acquisition of Limab earlier this year was expected to be financed partly by equity. SEK 66 m is however more than we anticipated and consequently the dilution will weigh on our valuation. The Q3-report was very much in line with expectations allthough order bookings are still quite weak and some cause for concern.